Additional chromosome abnormalities in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy

Haematologica

Volumn 95, Issue 3, 2010, Pages 424-431

  Cervera, José ^a   Montesinos, Pau ^a   Hernández Rivas, Jesús M ^b   Calasanz, María J ^c   Aventín, Anna ^d   Ferro, María T ^e   Luño, Elisa ^f   Sánchez, Javier ^g   Vellenga, Edo ^h   Rayón, Chelo ^f   Milone, Gustavo ⁱ   De La Serna, Javier ^j   Rivas, Concha ^k   González, José D ^l   Tormo, Mar ^m   Amutio, Elena ⁿ   González, Marcos ^b   Brunet, Salut ^d   Lowenberg, Bob ^o   Sanz, Miguel A ^a  

^a HOSPITAL UNIVERSITARIO LA FE   (Spain)

^b HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^c UNIVERSITY OF NAVARRA   (Spain)

^d Hospital Sant Pau   (Spain)

^e HOSPITAL RAMÓN Y CAJAL   (Spain)

^f HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^g HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^h UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

ⁱ Fundacion para Combatir La Leucemia   (Argentina)

^j HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^k HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

^l HOSPITAL UNIVERSITARIO INSULAR DE GRAN CANARIA   (Spain)

^m HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

ⁿ HOSPITAL DE CRUCES   (Spain)

^o ERASMUS MEDICAL CENTER   (Netherlands)

more..

Author keywords

Acute promyelocytic leukemia; Additional chromosomal abnormalities; All trans retinoic acid; Anthracycline; Prognostic factors

Indexed keywords

IDARUBICIN; MERCAPTOPURINE; METHOTREXATE; MITOXANTRONE; RETINOIC ACID;

ARTICLE; BLOOD CLOTTING DISORDER; CANCER COMBINATION CHEMOTHERAPY; CANCER RELAPSE; CHROMOSOME 7Q; CHROMOSOME ABERRATION; CYTOGENETICS; FEMALE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PROMYELOCYTIC LEUKEMIA; SCORING SYSTEM; THROMBOCYTE COUNT; TRISOMY 8;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CHILD, PRESCHOOL; CHROMOSOME ABERRATIONS; CHROMOSOMES, HUMAN, PAIR 15; CHROMOSOMES, HUMAN, PAIR 17; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; LEUKEMIA, PROMYELOCYTIC, ACUTE; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; ONCOGENE PROTEINS, FUSION; REMISSION INDUCTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SURVIVAL RATE; TRANSLOCATION, GENETIC; TREATMENT OUTCOME; TRETINOIN; YOUNG ADULT;

EID: 77949733334     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2009.013243     Document Type: Article

References (25)

1. Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, Harrison G, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. Blood. 1998;92(7):2322-33.
2. Slovak ML, Kopecky KJ, Cassileth PA, Harrington DH, Theil KS, Mohamed A, et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group study. Blood. 2000;96(13):4075-83.
3. Byrd JC, Mrózek K, Dodge RK, Carroll AJ, Edwards CG, Arthur DC, et al. Pre-treatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood. 2002;100(13):4325-36.
4. Slack JL, Arthur DC, Lawrence D, Mrózek K, Mayer RJ, Davey FR, et al. Secondary cytogenetic changes in acute promyelocytic leukemia - prognostic importance in patients treated with chemotherapy alone and association with the intron 3 breakpoint of the PML gene: a Cancer and Leukemia Group B study. J Clin Oncol. 1997;15(5):1786-95.
5. Hiorns LR, Swansbury GJ, Mehta J, Min T, Dainton MG, Treleaven J, et al. Additional chromosome abnormalities confer worse prognosis in acute promyelocytic leukaemia. Br J Haematol. 1997;96(2):314-21.
6. De Botton S, Chevret S, Sanz M, Dombret H, Thomas X, Guerci A, et al. Additional chromosomal abnormalities in patients with acute promyelocytic leukaemia (APL) do not confer poor prognosis: results of APL 93 trial. Br J Haematol. 2000;111(3):801-6.
7. Hernández JM, Martín G, Gutiérrez NC, Cervera J, Ferro MT, Calasanz MJ, et al. Additional cytogenetic changes do not influence the outcome of patients with newly diagnosed acute promyelocytic leukemia treated with an ATRA plus anthracyclin based protocol. A report of the Spanish group PETHEMA. Haematologica. 2001;86(8):807-13.
8. Schlenk RF, Germing U, Hartmann F, Glasmacher A, Fischer JT, del Valle y Fuentes F, et al. High-dose cytarabine and mitoxantrone in consolidation therapy for acute promyelocytic leukemia. Leukemia. 2005;19(6):978-83.
9. Sanz MA, Martín G, Rayón C, Esteve J, González M, Díaz-Mediavilla J, et al. A modified AIDA protocol with anthracycline-based consolidation results in high antileukemic efficacy and reduced toxicity in newly diagnosed PML/RARα- positive acute promyelocytic leukemia. Blood. 1999;94(9):3015-21.
10. Sanz MA, Martín G, González M, León A, Rayón C, Rivas C, et al. Risk-adapted treatment of acute promyelocytic leukemia with all-trans retinoic acid and anthracycline monochemotherapy: a multicenter study by the PETHEMA Group. Blood. 2004;103(4):1237-43.
11. Sanz MA, Montesinos P, Vellenga E, Rayón C, de la Serna J, Parody R, et al. Risk-adapted treatment of acute promyelocytic leukemia with all-trans-retinoic acid and anthracycline monochemotherapy: longterm outcome of the LPA 99 multicenter study by the PETHEMA group. Blood. 2008; 112(8):3130-4.
12. Gomis F, Sanz J, Sempere A, Plumé G, Senent ML, Pérez ML, et al. Immunofluorescent analysis with the anti-PML monoclonal antibody PG-M3 for rapid and accurate genetic diagnosis of acute promyelocytic leukemia. Ann Hematol. 2004;83(11):687-90.
13. Mitelman F (ed). ISCN. Guidelines for Cancer Cytogenetics. Supplement to: An International System for Human Cytogenetic Nomenclature. Basel: S. Karger; 1995.
14. Grimwade D, Biondi A, Mozziconacci MJ, Hagemeijer A, Berger R, Neat M, et al. Characterization of acute promyelocytic leukemia cases lacking the classic t(15;17): results of the European Working Party. Groupe Francais de Cytogenetique Hematologique, Groupe de Francais d'Hematologie Cellulaire, UK Cancer Cytogenetics Group and BIOMED 1 European Community-Concerted Action "Molecular Cytogenetic Diagnosis in Haematological Malignancies". Blood. 2000;96(4):1297-308.
15. Bolufer P, Barragán E, Sánz MA, Martín G, Bornstein R, Colomer D, et al. Preliminary experience in external quality control of RT-PCR PML-RAR alpha detection in promyelocytic leukemia. Leukemia. 1998;12(12):2024-8.
16. Bolufer P, Lo Coco F, Grimwade D, Barragán E, Diverio D, Cassinat B, et al. Variability in the levels of PML-RAR alpha fusion transcripts detected by the laboratories participating in an external quality control program using several reverse transcription polymerase chain reaction protocols. Haematologica. 2001;86(6):570-6.
17. Sanz MA, Lo Coco F, Martín G, Avvisati G, Rayón C, Barbui T, et al. Definition of relapse risk and role of non-anthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA cooperative groups. Blood. 2000;96(4):1247-53.
18. de la Serna J, Montesinos P, Vellenga E, Rayón C, Parody R, León A, et al. Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and idarubicin. Blood. 2008;111(7):3395-402.
19. Cheson BD, Bennett JM, Kopecky KJ, Büchner T, Willman CL, Estey EH, et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol. 2003;21(24):4642-9.
20. Kaplan EL, Meier P. Nonparametric estimations from incomplete observations. J Am Stat Assoc. 1958;53:457-81.
21. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep. 1966;50(3):163-70.
22. Cox DR. Regression models and life tables (with discussion). J R Stat Soc B. 1972;34:187-220.
23. Schoch C, Haase D, Haferlach T, Freund M, Link H, Lengfelder E, et al. Incidence and implication of additional chromosome aberrations in acute promyelocytic leukaemia with translocation t(15;17) (q22;q21): a report on 50 patients. Br J Haematol. 1996;94(3):493-500.
24. Gale RE, Hills R, Pizzey AR, Kottaridis PD, Swirsky D, Gilkes AF, et al. Relationship between FLT3 mutation status, biologic characteristics, and response to targeted therapy in acute promyelocytic leukemia. Blood. 2005;106(12):3768-76.
25. Akagi T, Shih LY, Kato M, Kawamata N, Yamamoto G, Sanada M, et al. Hidden abnormalities and novel classification of t(15 ;17) acute promyelocytic leukemia (APL) based on genomic alterations. Blood. 2009;113(8):1741-8.